AnGes, Inc. (TYO:4563)
Japan · Delayed Price · Currency is JPY 60.00
+1.00 (1.67%)
Jul 17, 2025, 10:49 AM JST
AnGes Company Description
AnGes, Inc. engages in the research and development of gene-based medical products.
It develops HGF gene therapy product for the treatment of ischemic diseases; NF-κB Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine.
The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
AnGes, Inc.
| Country | Japan |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Ei Yamada |
Contact Details
Address: Saito Bio-Incubator Ibaraki, 567-0085 Japan | |
| Website | anges.co.jp |
Stock Details
| Ticker Symbol | 4563 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3127700007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ei Yamada | Chief Executive Officer |